9713 Key West Avenue
Suite 400
Rockville, MD 20850
United States
301 944 1700
https://www.maxcyte.com
Secteur(s): Healthcare
Secteur d’activité: Medical Devices
Employés à temps plein: 143
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Mr. Maher Masoud | President, CEO & Director | 650,98k | S.O. | 1976 |
Mr. Douglas Arthur Doerfler | Founder | 2,34M | S.O. | 1956 |
Mr. Douglas J. Swirsky CFA, CPA | Chief Financial Officer | 607,42k | S.O. | 1969 |
Mr. Jay Gelfman | Senior Vice President of Operations | S.O. | S.O. | S.O. |
Mr. Ronald Evan Holtz CPA, Ph.D. | Executive Vice President of Administration | 649,38k | S.O. | 1958 |
Mr. David Sandoval | Senior Vice President, General Counsel & Corporate Secretary | S.O. | S.O. | S.O. |
Mr. Thomas Michael Ross | Executive Vice President of Global Sales | S.O. | S.O. | 1961 |
Mr. Jack Horgan | Vice President of Corporate Development | S.O. | S.O. | S.O. |
Ms. Jill Mayer | Senior Vice President of Human Resources | S.O. | S.O. | S.O. |
Dr. J. Stark Thompson Ph.D. | Consultant | 84,71k | S.O. | 1942 |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes next-generation cell therapies in the United States and internationally. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. It licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
L’ISS Governance QualityScore de MaxCyte, Inc. en date du 1 juin 2024 est 7. Les scores principaux sont Audit : 2; Société : 8; Droits des actionnaires : 8; Compensation : 8.